Association of cyclinD1 copy number changes with histological type in ovarian tumors

REFERENCES

• Henrikson R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993; 53: 4550–4.
   PubMedGoogle Scholar
• Tyson FL, Boyer CM, Kaufman R, et al. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 1991; 165: 640–6.
   PubMed Web of Science ®Google Scholar
• Volm M, Koomagi R, Kaufmann M, Mattem J, Stammler G. Microvessel density expression of proto-oncogenes, resistance-related proteins and incidence of metastases in primary ovarian carcinomas. Clin Exp Metastasis 1996; 14: 209–14.
   Google Scholar
• Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128–32.
   PubMed Web of Science ®Google Scholar
• Wang MB, Alavi S, Engstrom M, et al. Detection of chromo-some 11q13 amplification in head and neck cancer using fluorescence in situ hybridization. Anticancer Res 1999; 19: 925–31.
   PubMedGoogle Scholar
• Hui R, Campbell DH, Lee CS, et al. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 1997; 15: 1617–23.
   PubMed Web of Science ®Google Scholar
• Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998; 51: 1–7.
   PubMedGoogle Scholar
• Dhar KK, Branigan K, Parkes J, et al. Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br J Cancer 1999; 81: 1174–81.
   PubMedGoogle Scholar
• Shigemasa K, Tanimoto H, Parham GP, Parmley TH, Ohama K, O'Brien TJ. Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 1999; 6: 102–8.
   Google Scholar
• Barbieri F, Cagnoli M, Ragni N, Foglia G, Bruzzo C, Pedulla F, Alama A. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors. Clin Cancer Res 1999; 5: 1837–42.
   Google Scholar
• Sui L, Tokuda M, Ohno M, Hatase O, Hando T. The concurrent expression of p27(kipl) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol 1999; 73: 202–9.
   Google Scholar
• Kusume T, Tsuda H, Kawabata M, et al. The p16-cyclin D11 CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999; 5: 4152–7.
   PubMed Web of Science ®Google Scholar
• Zhou P, Jiang W, Zhang YJ, et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995; 11: 571–80.
   PubMed Web of Science ®Google Scholar
• Diebold J, Mosinger K, Peiro G, et al. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridiza-tion. J Pathol 2000; 190: 564–71.
   Google Scholar
• Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5: 1966–75.
   PubMed Web of Science ®Google Scholar
• Schraml P, Schwerdtfeger G, Burkhalter F, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogenetarget in ovarian carcinoma. Am J Pathol 2003; 163: 985–92.
   Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarray for high-throughput molecular profiling of hun-dreds of specimens. Nat Med 1998; 4: 844–7.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, ed. Blaustein's pathology of the female genital tract. 4th ed. 1994: 705–939.
   Google Scholar
• Barbieri F, Cagnoli M, Ragni N, et al. Expression of Cyclin D1 correlates with malignancy in human ovarian tumors. Br J Cancer 1997; 75: 1263–8.
   PubMedGoogle Scholar
• Peiro G, Diebold J, Lohrs U. CAS (cellular apoptosis suscept-ibility) gene expression in ovarian carcinoma: correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. Am J Clin Pathol 2002; 118: 922–9.
   Google Scholar
• Enamoto T, Weghorsst C, Inoue M, Tanizawa O, Rice J. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991; 139: 777–85.
   Google Scholar
• Ichikawa Y, Nishida M, Suzuki H, et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994; 54: 33–5.
   PubMedGoogle Scholar
• Hung WC, Chai CY, Huang JS, et al. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum Pathol 1996; 27: 1324–8.
   PubMedGoogle Scholar
• Mhawech P, Kinkel K, Vlastos G, Pelte ME Ovarian carcino-mas in endometriosis: an immunohistochemical and compara-tive genomic hybridization study. Int .1 Gynecol Pathol 2002; 21: 401–6.
   PubMedGoogle Scholar
• Powell DE, Puls L, van Nagel I. Current concept in epithelial ovarian tumors: does benign to malignant transformation occur? Hum Pathol 1992; 23: 846–7.
   Google Scholar
• Puls LE, Powell DE, De Priest PD, Gallion HH, Hunter JE, Kryscio RJ. Transition from benign to malignant epithelium in mucinous and serous ovarian cysadenocarcinoma. Gynecol Oncol 1992; 47: 53–7.
   PubMed Web of Science ®Google Scholar